Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Needham reiterated a Hold rating on Globus Medical (NYSE:GMED), a medical device company with a market capitalization of $12 billion and an impressive revenue growth of 102% over the last twelve ...
Results that may be inaccessible to you are currently showing.